ABSTRACT
Background Primary aldosteronism (PA) is the predominant cause of secondary hypertension, leading to cardiovascular and renal damage via mechanisms such as oxidative stress and fibrosis. However, current epidemiology findings on the association between PA and estimated glomerular filtration rate (eGFR) remain inconsistent.
Methods A 1:1 sex- and age-matched case-control study was conducted among participants with PA, essential hypertension (EH), and normotension, with 204 participants in each group. Multiple linear regression was used to explore the correlations of PA, plasma aldosterone concentration (PAC), plasma renin concentration (PRC), and the aldosterone-to-renin ratio (ARR) with eGFR. Additionally, we performed a bidirectional two-sample mendelian randomization (MR) analysis to assess the causal relationship between PA and eGFR based on public genome wide association study (GWAS) databases, and established a multivariable MR (MVMR) analysis to further explore whether the causal effect of PA on eGFR decline independent of systolic (SBP) or diastolic blood pressure (DBP).
Results Multiple linear regression model showed that PA was associated with a decline eGFR (β = -0.234, [95% CI, -0.099, -0.039], P<0.001) after adjusted potential confounders. When stratified the PA patients into three groups according to the levels of PAC, PRC and ARR, patients in the highest PAC groups (β = -0.146 [95% CI, -0.093, -0.008], P =0.021), the lowest PRC group (β = -0.127 [95% CI, -0.084, -0.004], P =0.033), and the highest ARR group (β = -0.147 [95% CI, -0.092, -0.009], P =0.017) had much lower eGFR compared to the EH group. The inverse associations mentioned above remained significant even further adjusted for SBP or DBP, respectively. Besides, MR results indicated that genetically predicted PA was causally associated with a decline eGFR (β =-6.671×10-4[95% CI,-1.291×10-4,-4.328×10-5], P = 0.036), consistent effects were further detected in SBP (β =-1.121×10-3 [95% CI,-2.132×10-3,-1.110×10-4], P = 0.029) or DBP (β =-1.542×10-3,[95% CI,-2.693×10-3,-3.912×10-4], P = 0.008) adjusted model using MVMR analysis.
Conclusion Our study indicates that PA is causally associated with lower eGFR independent of blood pressure, and the adverse effects might be greater than negative controls or EH patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics and Human Subject Committee of Guangxi Medical University, China (No. 2022-0193), and the Ethics and Human Subject Committee of First Affiliated Hospital of Guangxi Medical University, China (No. 2023-K090-01).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data cannot be shared publicly because of privacy concerns. Data are available from the Ethics Committee of Guangxi Medical University (contact via Zengnan Mo) for researchers who meet the criteria for access to confidential data.
